Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maurie Markman

Showing results (71-80 of 413) with videos related to

Pageof 42
Sort By:
The Oncologist|October 27, 2005
Topotecan as second-line therapy for ovarian cancer: dosage versus toxicityMaurie Markman
Current Oncology Reports|August 7, 2002
Does palliative chemotherapy palliate?Maurie Markman
Cleveland Clinic Journal of Medicine|August 20, 2002
Progress in preventing chemotherapy-induced nausea and vomitingMaurie Markman
The Lancet. Oncology|May 7, 2003
Intraperitoneal antineoplastic drug delivery: rationale and resultsMaurie Markman
Cleveland Clinic Journal of Medicine|July 29, 2003
Are we winning or losing the war on cancer?Maurie Markman
Exploration of Targeted Anti-Tumor Therapy|January 26, 2026
The critical need for robust decision support in the era of precision cancer therapeuticsMaurie Markman
Oncology Nursing Forum|July 18, 2003
Outcomes of two antiemetic therapies are the sameMaurie Markman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2003
Role of intraperitoneal chemotherapy in the front-line settingMaurie Markman
Oncology|January 22, 2008
The rapidly changing oncology landscape: a time for transition in oncologyMaurie Markman
Nature Clinical Practice. Oncology|September 5, 2007
The CA125 antigen level as a prognostic versus a predictive test in epithelial ovarian cancerMaurie Markman
Pageof 42

Showing results (71-80 of 413) with videos related to

Sort By:
Pageof 42
The Oncologist|October 27, 2005
Topotecan as second-line therapy for ovarian cancer: dosage versus toxicityMaurie Markman
Current Oncology Reports|August 7, 2002
Does palliative chemotherapy palliate?Maurie Markman
Cleveland Clinic Journal of Medicine|August 20, 2002
Progress in preventing chemotherapy-induced nausea and vomitingMaurie Markman
The Lancet. Oncology|May 7, 2003
Intraperitoneal antineoplastic drug delivery: rationale and resultsMaurie Markman
Cleveland Clinic Journal of Medicine|July 29, 2003
Are we winning or losing the war on cancer?Maurie Markman
Exploration of Targeted Anti-Tumor Therapy|January 26, 2026
The critical need for robust decision support in the era of precision cancer therapeuticsMaurie Markman
Oncology Nursing Forum|July 18, 2003
Outcomes of two antiemetic therapies are the sameMaurie Markman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2003
Role of intraperitoneal chemotherapy in the front-line settingMaurie Markman
Oncology|January 22, 2008
The rapidly changing oncology landscape: a time for transition in oncologyMaurie Markman
Nature Clinical Practice. Oncology|September 5, 2007
The CA125 antigen level as a prognostic versus a predictive test in epithelial ovarian cancerMaurie Markman
Pageof 42